Cizzle Bio's CIZ1B Biomarker Blood Test Advances Early Lung Cancer Detection at Summit

Advancements in Early Lung Cancer Detection: Cizzle Bio at the Next Generation Dx Summit

Cizzle Bio Inc., a Texas-based biotechnology company dedicated to innovating cancer diagnostics, recently participated in the prestigious 18th Annual Next Generation Dx Summit held in Washington, D.C. Their focus was on the CIZ1B Biomarker Blood Test, a promising tool aimed at detecting lung cancer in its early stages.

During the summit, Dr. Lary A. Robinson, a leading authority from the Lung Cancer Early Detection (LEAD) Center at Moffitt Cancer Center, presented findings that could reshape how early lung cancer is detected and managed. His presentation, titled "Potential of the CIZ1B Biomarker to Redefine Early Lung Cancer Detection," highlighted the ongoing clinical study at Moffitt Cancer Center, where the CIZ1B test is currently being evaluated on patients with identified lung nodules.

One of the critical issues discussed was the prevalent challenges in early lung cancer detection. A staggering 1.6 million lung nodules are detected each year in the U.S. alone, leading to a pressing need for effective diagnostic tools to determine which of these nodules require further evaluation. Dr. Robinson pointed out that many patients may not participate in low-dose CT screening, and there remains uncertainty about the management of indeterminate pulmonary nodules.

He emphasized, "A reliable blood test could help assess indeterminate lung nodules and reduce unnecessary invasive procedures." This capability could be vital in providing additional information for clinicians monitoring patients post-treatment.

The CIZ1B biomarker derives from 30 years of research conducted at the University of York and is specifically associated with early-stage lung cancer detection. A recent study published in The Journal of Applied Laboratory Medicine found that the ELISA assay for CIZ1B demonstrated an impressive sensitivity of approximately 94%, with a negative predictive value of 97%. These promising statistics set a solid foundation for the biomarker's application in clinical settings.

The clinical study at Moffitt is assessing how effectively CIZ1B can differentiate between malignant and benign nodules, stratify the risk of recurrence in patients after curative treatment, and aid in monitoring for any recurrence or secondary lung cancers. Comparative analysis will take place between the blood tests conducted at initial evaluations and the eventual clinical diagnoses, with serial testing also on the agenda during follow-up evaluations.

Bill Behnke, CEO of Cizzle Bio, remarked on the significance of Dr. Robinson's presentation, acknowledging the clinical insights into the difficulties faced by physicians when trying to detect lung cancer earlier. He stated, "The Moffitt study is pivotal in building the clinical evidence needed to understand where CIZ1B may provide meaningful information in the lung cancer care pathway."

In July 2026, Cizzle Bio launched the CIZ1B Biomarker Blood Test for licensed healthcare providers within the Dallas-Fort Worth and San Antonio markets, marking an important milestone in the national rollout of the test. With its proprietary licensing rights for CIZ1B in the United States, Canada, and the Caribbean, Cizzle Bio aims to empower patients and healthcare providers alike, promoting innovative diagnostics in the fight against cancer.

Cizzle Bio continues to focus on pioneering biomarker blood tests that revolutionize early detection methods and improve overall patient outcomes, with a heartfelt commitment to compassion and innovation in the healthcare landscape. To learn more about Cizzle Bio and its endeavors, visit CizzleBio.com.